StimCardio closes $30 million for a therapeutic wearable
Metis Medtech led financing for the planned NeuroPulse 2 pivotal study and FDA submission preparation for investigational wearable Rhyvive.
StimCardio wants treatment for atrial fibrillation to continue beyond the hospital procedure. Its investigational wearable is designed to support patients after catheter ablation.
What happened
On 29 October, StimCardio closed an oversubscribed $30 million Series A, led by Metis Medtech, with Catalyst Health Ventures and other investors participating.
The financing is intended to support the planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission. Its lead product, Rhyvive, is a wrist-worn device that combines physiological sensing with non-invasive nerve stimulation, with the goal of reducing recurrent atrial arrhythmias.
Why it matters
A wearable treatment could extend care into everyday life, but its value depends on clinical evidence of meaningful benefit. The proposed study is an important step in evaluating whether the approach can improve outcomes alongside existing treatment.
The bigger picture
Rhyvive remains investigational and has no regulatory clearance or approval. Financing the next study provides resources to test the product; it does not establish effectiveness or permission to sell it. Clinical results and regulatory review remain the key milestones.